AMAG Pharmaceuticals, Inc. (AMAG)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
William K. Heiden
Employees:
467
1100 WINTER STREET, WALTHAM, MA 02451
6174983300

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.

Data derived from most recent annual or quarterly report
Market Cap 477.47 Million Shares Outstanding34.725 Million Avg 30-day Volume 1.378 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.83
Price to Revenue1.0747 Debt to Equity1.1301 EBITDA-151.707 Million
Price to Book Value1.2748 Operating Margin-72.2687 Enterprise Value446.801 Million
Current Ratio1.75 EPS Growth0.211 Quick Ratio1.46
1 Yr BETA 0.9802 52-week High/Low 0.0 / Profit Margin-75.2418
Operating Cash Flow Growth79.4121 Altman Z-Score-1.8895 Free Cash Flow to Firm 32.269 Million
View SEC Filings from AMAG instead.

View recent insider trading info

Funds Holding AMAG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMAG

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-10-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-17:
    Item 8.01: Other Events
  • 8-K: filed on 2020-08-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-11:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-04-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SULAT JAMES R

    • Director
    No longer subject to file 2020-11-16 0

    SCOON DAVEY

    • Director
    No longer subject to file 2020-11-16 0

    SANTINI GINO

    • Director
    No longer subject to file 2020-11-16 0

    MYERS SCOTT DUNSETH PRESIDENT & CEO

    • Officer
    • Director
    No longer subject to file 2020-11-16 0

    VITTIGLIO JOSEPH CHIEF BUSINESS OFFICER, GC

    • Officer
    No longer subject to file 2020-11-16 0

    FALLON JOHN A.

    • Director
    No longer subject to file 2020-11-16 0

    PHILLIPS ANNE M.

    • Director
    No longer subject to file 2020-11-16 0

    CALIGAN PARTNERS LP

    • 10% Owner
    No longer subject to file 2020-11-16 0

    FONTEYNE PAUL R.

    • Director
    No longer subject to file 2020-11-16 0

    O'BRIEN KATHRINE

    • Director
    No longer subject to file 2020-11-16 0

    CASCIANO ANTHONY CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2020-11-16 0

    JOHNSON DAVID EDWARD

    • Director
    • 10% Owner
    No longer subject to file 2020-11-16 0

    SCHICK KELLY CHIEF HUMAN RESOURCES OFFICER

    • Officer
    No longer subject to file 2020-11-16 0

    PIEKOS BRIAN CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2020-11-16 0

    CAMBER CAPITAL MANAGEMENT LP

    • 10% Owner
    0 2020-10-01 0

    ARMISTICE CAPITAL, LLC

    ARMISTICE CAPITAL MASTER FUND LTD.

    BOYD STEVEN

    • 10% Owner
    4,468,000 2020-03-16 0

    MYLES EDWARD H COO & CFO

    • Officer
    98,659 2020-03-10 0

    HEIDEN WILLIAM K PRESIDENT & CEO

    • Officer
    • Director
    424,612 2020-03-02 0

    KROP JULIE CHIEF MEDICAL OFFICER

    • Officer
    73,044 2020-03-02 0

    SHEA KENNETH

    • 10% Owner
    • SEE REMARKS
    5,000 2019-09-04 0

    CALIGAN PARTNERS LP

    MERKSAMER SAMUEL J.

    JOHNSON DAVID EDWARD

    • 10% Owner
    3,499,428 2019-08-12 0

    PEREZ ROBERT J

    • Director
    33,629 2019-05-16 0

    DEPTULA BARBARA

    • Director
    26,354 2019-05-16 0

    BOLGIANO ELIZABETH SCOTT CHIEF HUMAN RESOURCES OFFICER

    • Officer
    74,847 2019-05-09 0

    BUTCHER JAMES ALAN EVP, CHIEF BUSINESS OFFICER

    • Officer
    50,628 2019-04-30 0

    GRUND NICHOLAS CHIEF COMMERCIAL OFFICER

    • Officer
    84,805 2019-03-02 0

    RUSSELL LESLEY

    • Director
    24,913 2018-06-07 0

    KELLEY BRIAN P

    • Director
    5,571 2017-05-18 0

    THOMAS FRANK E PRESIDENT & COO

    • Officer
    138,195 2017-02-23 0

    WILSON KENNETH H SVP, SALES AND MARKETING

    • Officer
    23,387 2015-12-02 0

    CROUSE GEOFFREY EVP

    • Officer
    18,750 2015-08-31 0

    HOLMES SCOTT A SVP, FINANCE AND TREASURER

    • Officer
    51,958 2015-06-15 0

    TOWNSEND SCOTT B SVP, GENERAL COUNSEL

    • Officer
    56,851 2015-03-03 0

    JORDAN EDWARD P. SVP, SALES AND MARKETING

    • Officer
    39,213 2015-03-03 0

    ADAGE CAPITAL PARTNERS GP LLC

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    No longer subject to file 2015-01-07 0

    CAFFE STEVEN SVP, CH. DEV. AND REG. OFFICER

    • Officer
    59,400 2014-08-19 0

    WHITE CHRISTOPHER G CHIEF BUSINESS OFFICER

    • Officer
    28,400 2014-02-27 0

    NARACHI MICHAEL

    • Director
    23,900 2013-05-23 0

    MADISON GREG EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    18,800 2013-02-28 0

    ALLEN LEE F MD PHD EVP, CHIEF MEDICAL OFFICER

    • Officer
    2,229 2012-08-06 0

    DE SILVA RAJIV

    • Director
    14,822 2012-05-24 0

    BONVENTRE JOSEPH VINCENT

    • Director
    0 2012-05-23 0

    FARMER JOSEPH L GENERAL COUNSEL, SVP

    • Officer
    0 2012-02-24 0

    ZIEZIULA GARY J EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    2,500 2011-07-29 0

    ENGLISH EDWARD C VP, CONTROLLER, INTERIM CFO

    • Officer
    88 2011-06-24 0

    ARKOWITZ DAVID EVP, CFO, CBO

    • Officer
    1,806 2011-05-31 0

    ZWANZIGER RON

    • Director
    0 2011-05-24 0

    PEREIRA BRIAN JG PRESIDENT AND CEO

    • Officer
    • Director
    5,000 2011-03-01 0

    ZAYAS RICARDO SVP, OPERATIONS

    • Officer
    0 2011-01-07 0

    HEALEY TIMOTHY G SVP, COMMERCIAL OPERATIONS

    • Officer
    0 2010-02-24 0

    SKALETSKY MARK B

    • Director
    0 2008-12-19 0

    LOBERG MICHAEL D

    • Director
    0 2008-12-19 0

    LEWIS JEROME M SVP OF SCIENTIFIC OPERATIONS

    • Officer
    0 2008-08-05 0

    BRENNER LOUIS MD SENIOR VICE PRESIDENT

    • Officer
    36,500 2007-11-12 0

    GOLDSTEIN JEROME EXEC. CHAIRMAN & TREASURER

    • Officer
    • Director
    420,504 2007-04-16 0

    AVALLONE MICHAEL N VP - FINANCE & CFO

    • Officer
    4,250 2007-02-02 0

    BLOCH SHELDON L

    • Director
    68,973 2006-11-27 0

    ROBERTS EDWARD B

    • Director
    3,834 2006-11-07 0

    STEINMAN THEODORE I

    • Director
    3,834 2006-11-07 0

    GREAT POINT PARTNERS LLC

    JAY JEFFREY R

    • 10% Owner
    413,918 2006-03-21 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    • 10% Owner
    • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
    1,028,733 2006-01-12 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments